Rare diseases are individually uncommon but collectively significant in the Irish healthcare sector. On 28 February 2026, Minister Carroll MacNeill confirmed progress on the National Rare Disease Strategy 2025–2030, including an implementation plan due in 2026, a Rare Disease Education Programme for all healthcare professionals, and €8 million in committed funding. For private hospitals with specialist capabilities, this is an opening to serve a population of 300,000 that deserves faster access to expert care.

The strategy deserves commendation as a comprehensive, patient-centred framework. Its move into active implementation in 2026 creates a direct opportunity for private healthcare providers. Private hospitals that register specialist expertise with the HSE National Rare Disease Office, engage with European Reference Networks, and design structured rare disease clinics will deliver healthcare excellence to one of the most underserved and clinically complex patient populations in the Irish health system.

The National Rare Disease Strategy 2025–2030 emphasises integrated, multidisciplinary care pathways and improved transition from paediatric to adult services. These are precisely the service design elements that healthcare providers with genetics, metabolic medicine, and specialist medical capabilities can deliver with speed and quality. Rare disease patients typically wait years for diagnosis and specialist review; a structured private pathway offering faster access to expert multidisciplinary assessment would transform patient experience outcomes for this cohort.

The insurance context supports investment. The Insurance Ireland and Milliman report, published December 2025, confirms private health insurance paid out over €3 billion in claims in 2024. Rare disease patients are among the most complex insured cohorts. Healthcare professionals with clinical genetics, immunology, or metabolic medicine expertise are the foundation of any credible rare disease offering. Investing in healthcare technology for genetic testing, genomic interpretation, and multidisciplinary case conferencing will distinguish specialist rare disease centres from general private hospital services.

The European Reference Network dimension adds strategic depth. The strategy prioritises full ERN integration, giving participating clinicians access to European specialist expertise for complex diagnoses. Healthcare leadership that secures ERN participation for private hospital specialists will demonstrate operational excellence in healthcare at an international level, building credibility with the rare disease patient community, with the HSE National Rare Disease Office, and with insurers managing the high-cost claims of rare disease patients.

Three actions will position private hospitals within this strategy. First, register relevant specialist consultants with the HSE National Rare Disease Office to enter the national referral network. Second, convene a multidisciplinary rare disease clinic combining genetics, metabolic medicine, and specialist physician input. Third, apply healthcare leadership and management discipline and medical innovation to building genomic and diagnostic infrastructure that supports faster identification, shorter diagnostic journeys, and the longitudinal care relationships rare disease patients require.

Ireland’s 300,000 people living with rare diseases deserve faster, more coordinated expert care. Irish private healthcare organisations with the right clinical capabilities are well placed to contribute. Those that bring healthcare innovation and genuine specialist commitment to rare disease pathways will serve a patient population that has long waited for a system willing to see and respond to its complexity.